Abstract:The sodium/glucose cotransporters (SGLT1 and SGLT2) transport glucose across the intestinal brush border and kidney tubule. Dual SGLT1/2 inhibition could reduce hyperglycemia more than SGLT2-selective inhibition in patients with type 2 diabetes. However, questions remain about altered gastrointestinal (GI) luminal glucose and tolerability, and this was evaluated in slc5a1-/- mice or with a potent dual inhibitor (compound 8; SGLT1 Ki = 1.5 ± 0.5 nM 100-fold greater potency than phlorizin; SGLT2 Ki = 0.4 ± 0.2 nM). 13C6-glucose uptake was quantified in slc5a1-/- mice and in isolated rat jejunum. Urinary glucose excretion (UGE), blood glucose (Sprague-Dawley rats), glucagon-like peptide 1 (GLP-1), and hemoglobin A1c (HbA1c) levels (Zucker diabetic fatty rats) were measured. Intestinal adaptation and rRNA gene sequencing was analyzed in C57Bl/6 mice. The blood 13C6-glucose area under the curve (AUC) was reduced in the absence of SGLT1 by 75% (245 ± 6 vs. 64 ± 6 mg/dl⋅h in wild-type vs. slc5a1-/- mice) and compound 8 inhibited its transport up to 50% in isolated rat jejunum. Compound 8 reduced glucose excursion more than SGLT2-selective inhibition (e.g., AUC = 129 ± 3 vs. 249 ± 5 mg/dl⋅h for 1 mg/kg compound 8 vs. dapagliflozin) with similar UGE but a lower renal glucose excretion threshold. In Zucker diabetic fatty rats, compound 8 decreased HbA1c and increased total GLP-1 without changes in jejunum SGLT1 expression, mucosal weight, or villus length. Overall, compound 8 (1 mg/kg for 6 days) did not increase cecal glucose concentrations or bacterial diversity in C57BL/6 mice. In conclusion, potent dual SGLT1/2 inhibition lowers blood glucose by reducing intestinal glucose absorption and the renal glucose threshold but minimally impacts the intestinal mucosa or luminal microbiota in chow-fed rodents.

C-Aryl Glucosides Substituted at the 4′-Position As Potent and Selective Renal Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

Aglycone Exploration of C-arylglucoside Inhibitors of Renal Sodium-Dependent Glucose Transporter SGLT2.

Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes.

Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus.

EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats

Shr3824, A Novel Selective Inhibitor of Renal Sodium Glucose Cotransporter 2, Exhibits Antidiabetic Efficacy in Rodent Models

Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents

In-silico screening and identification of glycomimetic as potential human sodium-glucose co-transporter 2 inhibitor

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (sglt2) Inhibitor for the Treatment of Type 2 Diabetes

Discovery of New α-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation

Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

New selective inhibitors of α‐glucosidase for the treatment of type 2 diabetes mellitus

Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus

Synthesis of Novel N-glycoside Derivatives Via CuSCN-catalyzed Reactions and Their SGLT2 Inhibition Activities

SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE

Impact of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Atherosclerosis: from Pharmacology to Pre-Clinical and Clinical Therapeutics

Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

Synthesis, Crystal structure, Spectral analysis, DFT calculations, Docking studies, in vitro biological activity evaluation and in silico drug-likeness prediction of a novel L-xylose derivative